Bowel Disease Drug of Pfizer Succeeds in Second Late-Stage Study
On Tuesday, 29th March 2022, the pharmaceutical company ‘Pfizer Inc’ said that, the company’s experimental treatment for an inflammatory bowel disease, which has been acquired in 2021 as a part of the company’s 6.7 billion dollars Arena Pharmaceuticals deal has been succeeded in the second late-stage study. Etrasimod of Pfizer has successfully showed improvement in […]
Continue Reading